AbCellera Biologics (ABCL) to Release Quarterly Earnings on Thursday

AbCellera Biologics (NASDAQ:ABCL) is anticipated to post its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect AbCellera Biologics to post earnings of ($0.15) per share and revenue of $7.58 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

AbCellera Biologics Trading Up 1.2 %

NASDAQ ABCL opened at $3.47 on Thursday. The firm has a market capitalization of $1.02 billion, a P/E ratio of -5.69 and a beta of 0.42. The business has a fifty day simple moving average of $3.08 and a 200 day simple moving average of $2.83. AbCellera Biologics has a 12 month low of $2.34 and a 12 month high of $5.45.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. KeyCorp reduced their price objective on AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Stifel Nicolaus reissued a “buy” rating and set a $12.00 price objective (down previously from $14.00) on shares of AbCellera Biologics in a report on Tuesday, November 5th. Finally, Benchmark reissued a “hold” rating on shares of AbCellera Biologics in a report on Tuesday, November 5th.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.